Log in

NASDAQ:PRTKParatek Pharmaceuticals Stock Price, Forecast & News

$4.51
+0.10 (+2.27 %)
(As of 08/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.35
Now: $4.51
$4.56
50-Day Range
$4.37
MA: $4.84
$5.52
52-Week Range
$2.50
Now: $4.51
$6.41
Volume244,577 shs
Average Volume678,063 shs
Market Capitalization$194.52 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Read More
Paratek Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PRTK
Previous SymbolNASDAQ:TSPT
CUSIP89354M10
Phone617-807-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.54 million
Book Value($1.19) per share

Profitability

Net Income$-128,790,000.00
Net Margins-528.28%

Miscellaneous

Employees101
Market Cap$194.52 million
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$4.51
+0.10 (+2.27 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

How has Paratek Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has increased by 15.9% and is now trading at $4.51.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Paratek Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Paratek Pharmaceuticals
.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Paratek Pharmaceuticals
.

How can I listen to Paratek Pharmaceuticals' earnings call?

Paratek Pharmaceuticals will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) released its quarterly earnings data on Monday, May, 11th. The specialty pharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.14. The specialty pharmaceutical company earned $7.92 million during the quarter, compared to analysts' expectations of $7.75 million.
View Paratek Pharmaceuticals' earnings history
.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $75-80 million, compared to the consensus revenue estimate of $81.12 million.

What price target have analysts set for PRTK?

6 equities research analysts have issued 1 year target prices for Paratek Pharmaceuticals' shares. Their forecasts range from $6.00 to $36.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $18.50 in the next twelve months. This suggests a possible upside of 310.2% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals
.

Has Paratek Pharmaceuticals been receiving favorable news coverage?

News articles about PRTK stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future.
View the latest news about Paratek Pharmaceuticals
.

Who are some of Paratek Pharmaceuticals' key competitors?

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Verastem (VSTM), TherapeuticsMD (TXMD), Energy Transfer LP Unit (ET), EXACT Sciences (EXAS), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:
  • Mr. Michael F. Bigham CPA, MBA, Exec. Chairman (Age 62, Pay $881.68k)
  • Dr. Evan Loh, CEO & Director (Age 61, Pay $906.9k)
  • Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 53, Pay $672.21k)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 58, Pay $586k)
  • Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 45)

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include General American Investors Co. Inc. (1.98%), Essex Investment Management Co. LLC (0.57%), ICM Asset Management Inc. WA (0.35%), SG Americas Securities LLC (0.05%), Leap Investments LP (0.05%) and UBS Group AG (0.03%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner, Thomas John Dietz and William M Haskel.
View institutional ownership trends for Paratek Pharmaceuticals
.

Which institutional investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including ICM Asset Management Inc. WA, and UBS Group AG. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner, and William M Haskel.
View insider buying and selling activity for Paratek Pharmaceuticals
.

Which institutional investors are buying Paratek Pharmaceuticals stock?

PRTK stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, General American Investors Co. Inc., SG Americas Securities LLC, and Leap Investments LP.
View insider buying and selling activity for Paratek Pharmaceuticals
.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $4.51.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $194.52 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.